Results 41 to 50 of about 2,622 (185)

Filgotinib suppresses HIV-1–driven gene transcription by inhibiting HIV-1 splicing and T cell activation [PDF]

, 2020
Despite effective antiretroviral therapy, HIV-1-infected cells continue to produce viral antigens and induce chronic immune exhaustion. We propose to identify HIV-1-suppressing agents that can inhibit HIV-1 reactivation and reduce HIV-1-induced immune ...
Ho, Ya-Chi, Deeks, Steven G, Jennifer Chiarella, Jenike, Katharine M, Rebecca Hoh, Steven G. Deeks, Yang-Hui Jimmy Yeh, Chiarella, Jennifer, Ya-Chi Ho, Rachela M. Calvi, Hoh, Rebecca, Katharine M. Jenike, Yeh, Yang-Hui Jimmy, Calvi, Rachela M   +13 more
core   +1 more source

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis

Frontiers in Bioscience-Landmark, 2023
Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes progressive joint damage. The Janus kinase (JAK) inhibitors (JAK-I) represent a new therapeutic option for RA patients, blocking the intracellular JAK-STAT pathway. Today,
Maurizio Benucci, Francesca Li Gobbi, Paola Fusi, Arianna Damiani, Edda Russo, Serena Guiducci, Mariangela Manfredi, Valentina Grossi, Maria Infantino, Amedeo Amedei   +9 more
doaj   +1 more source

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial [PDF]

, 2021
OBJECTIVES: To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial. METHODS: In the TORTUGA trial, patients with AS received filgotinib
Østergaard, Mikkel, Baraliakos, Xenofon, Maksymowych, Walter P., Maksymowych, Walter P, Hendrikx, Thijs, Besuyen, Robin, Landew, Robert, Barchuk, William, Landewé, Robert, Gilles, Leen, Liu, Ke   +10 more
core   +1 more source

Use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases: safety issues

Медицинский совет, 2021
There has been clear progress in rheumatology in recent decades with the introduction of genetically engineered biological drugs (GEBDs) as well as targeted baseline anti-inflammatory drugs, which include Janus kinase inhibitors (i-JAKs). To date, i-JAKs
B. S. Belov, N. V. Muravyeva, G. M. Tarasova, M. M. Baranova   +3 more
doaj   +1 more source

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal [PDF]

, 2021
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Gilead) of filgotinib (Jyseleca(TM)), as part of the single technology appraisal process, to submit evidence for its clinical and cost effectiveness for the treatment ...
Riemsma, R., Misso, K., Wijnen, B., Ahmadu, C., Kirwan, J.R., Kleijnen, J., Armstrong, N., Brandts, L., Joore, M.A., Fayter, D., Joore, M.A.; id_orcid, Grimm, S.E.   +11 more
core   +1 more source

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives

Patient Preference and Adherence, 2023
Yoshiya Tanaka,1 Mark C Genovese,2,3 Hironori Matsushima4 1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan; 2Division of Immunology and Rheumatology, Stanford ...
Tanaka Y, Genovese MC, Matsushima H
doaj  

Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry [PDF]

Objectives: The aim of this study was to evaluate the effectiveness and safety profile of filgotinib, a JAK1 preferential inhibitor, in rheumatoid arthritis (RA) patients included in Italian GISEA (Group for the Study of Early Arthritis) registry ...
Fornaro, Marco, De Stefano, Ludovico, Iannone, Florenzo, Bazzani, Chiara, Cauli, Alberto, Chimenti, Maria Sole, Atzeni, Fabiola, Ferraccioli, Gianfranco, Perniola, Simone, Congia, Mattia, Conti, Fabrizio, Lapadula, Giovanni, Bugatti, Serena, Caporali, Roberto, Biggioggero, Martina   +14 more
core   +3 more sources

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

Arthritis &Rheumatology, EarlyView.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal, Emily Moon, Georgios Kallikas   +2 more
wiley   +1 more source

Efficacy and Safety of Biologics and Small Molecule Drugs in the Treatment of Ulcerative Colitis: a Network Meta-analysis [PDF]

Zhongguo quanke yixue
Background Ulcerative colitis (UC) is a persistent immune-mediated inflammatory bowel disease characterized by chronic relapses and remissions. The management of UC remains a subject of contention, particularly as approximately half of the patients ...
TAN Shufa, ZHANG Leichang, GAO Qiangqiang, OU Yan, HUANG Shuilan
doaj   +1 more source